Sunday, November 4, 2007

3:00 PM-9:00 PM  **Exhibits**
Ballroom Foyer, Level 2

7:00 PM-9:15 PM  **Opening Session**
Ballroom 2, Level 2

- Welcome and Opening Remarks
  Edison T. Liu, Genome Institute of Singapore, Singapore
  William N. Hait, Johnson & Johnson Pharmaceutical Research & Development L.L.C., Raritan, NJ, USA
  Khaw Boon Wan, Ministry of Health, Singapore

- Keynote Addresses
  Stephen Quake, Stanford University, Stanford, CA, USA

9:15 PM-10:30 PM  **Opening Reception**
Ballroom Foyer, Level 2

Monday, November 5, 2007

8:00 AM-7:30 PM  **Exhibits**
Ballroom Foyer, Level 2

9:00 AM-11:30 AM  **Plenary Session 1:**
Frontier Technologies
Ballroom 2, Level 2

- Co-Chairpersons: Lance D. Miller, Genome Institute of Singapore, Singapore; Patrick B. Tan, National Cancer Centre, Singapore
- Whole Genome Chromatin Interaction Analysis of Transcriptional Regulation Networks in Human Cancer Cells*
  Yijun Ruan, Genome Institute of Singapore, Singapore
- A Systems Approach to Marker Guided Therapy in Breast Cancer
  Joe W. Gray, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
- Nanostructure Processing of Advanced Biomaterials and Biosystems*
  Jackie Yi-Ru Ying, Institute for Bioengineering and Nanotechnology, Singapore
- Righting the Cancer Epigenome by Epigenetic Therapy
  Peter A. Jones, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

11:30 AM-1:00 PM  **Poster Session A**
Ballroom 1, Level 2

1:00 PM-3:30 PM  **Plenary Session 2:**
Proteomics, Genomics, and Novel Therapeutics
Ballroom 2, Level 2

- Co-Chairpersons: Hew Choy Leong and John Wong, National University of Singapore, Singapore
- Plasma Biomarker Analysis via High Sensitivity, Targeted Analysis of N-glycosites
  Rudolf Hans Aebersold, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology, Zürich, Switzerland
- Drugging "Undruggable" Targets in Cancer*
  Gregory L. Verdine, Harvard University, Cambridge, MA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
Innovation and Cost-effectiveness of Cancer Therapy in the Systems Biomedicine Era  
Zhu Chen, Ministry of Health, Beijing, China

Breakthroughs in Cancer Biomarker Discovery Using Innovative Strategies  
Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Patterns of Somatic Mutation in Human Cancer Genomes*  
Michael R. Stratton, Wellcome Trust Sanger Institute, Cambridge, England

3:30 PM-4:00 PM  Refreshment Break  
Ballroom Foyer, Level 2

4:00 PM-5:30 PM  Panel Discussion:  
Culture, Policy, and Economics of Cancer Research and Cancer Care—A Global Perspective  
Ballroom 2, Level 2

Moderator: Edison T. Liu, Genome Institute of Singapore, Singapore

Panelists:  
William N. Hait, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA
Ying-I Yong, Ministry of Health, Singapore
Zhu Chen, Ministry of Health, Beijing, China
James H. Doroshow, National Cancer Institute, Bethesda, MD, USA

5:30 PM-7:30 PM  Poster Session A (continued)  
Ballroom 1, Level 2

Tuesday, November 6, 2007

8:00 AM-7:30 PM  Exhibits  
Ballroom Foyer, Level 2

9:00 AM-11:30 AM  Plenary Session 3:  
Animal Systems and Imaging in Cancer Research  
Ballroom 2, Level 2

Co-Chairpersons: Huynh Hung, National Cancer Centre, Singapore; Philip Ingham, Institute of Molecular and Cell Biology, Singapore

Harnessing Transposons for Cancer Gene Discovery  
Nancy A. Jenkins, Institute of Molecular and Cell Biology, Singapore

Genetic Screens for Potential Leukemia Stem Cell Maintenance Genes  
Neal G. Copeland, Institute of Molecular and Cell Biology, Singapore

Role of Polycomb Repressors in Stem Cells, Cancer, and Development*  
Maarten van Lohuizen, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Targeting the Notch Pathway in Cancer*  
A. Thomas Look, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Dissecting Signal Transduction Pathways In vivo with Dynamic Real-time Molecular Imaging*  
David Piwnica-Worms, Washington University School of Medicine, St. Louis, MO, USA

11:30 AM-1:00 PM  Poster Session B  
Ballroom 1, Level 2

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
1:00 PM - 3:00 PM  
**Plenary Session 4: New Trials and Genomic-Based Design**  
Ballroom 2, Level 2

**Co-Chairpersons:** Tan Say Beng, Clinical Trials and Epidemiology Research Unit, Singapore; Soo Kee Chee, National Cancer Centre, Singapore

Phase 0 Clinical Trials from Concept to Practice  
**James H. Doroshow,** National Cancer Institute, Bethesda, MD, USA

Design of Clinical Trials of Targeted Therapy*  
**Stephen L. George,** Duke University Medical Center, Durham, NC, USA

Genomic Strategies for Personalized Cancer Therapy*  
**Joseph R. Nevins,** Duke Institute for Genome Sciences & Policy, Durham, NC, USA

Discovery of Recurrent Gene Fusions in Prostate Cancer: A New Class of Biomarkers and Therapeutic Targets*  
**Arul M. Chinnaiyan,** University of Michigan Medical School, Ann Arbor, MI, USA

3:00 PM - 3:30 PM  
**Refreshment Break**  
Ballroom Foyer, Level 2

3:30 PM - 5:30 PM  
**Concurrent Session 1: Clinical Pharmacogenetics: Assessing Global Diversity**  
Meeting Room 301-302, Level 3

**Co-Chairpersons:** John C. W. Lim, Health Sciences Authority, Singapore; Tan Hang Chong, National Cancer Centre, Singapore

Unbiased Cell-Based Models to Identify Genetic Variants Associated with Chemotherapeutic Induced Toxicity*  
**M. Eileen Dolan,** University of Chicago, Chicago, IL, USA

Ethnicity and Pharmacogenetics of Anticancer Therapy*  
**Boon Cher Goh,** Yong Loo Lin School of Medicine, Singapore

Personalized Chemotherapy: The Case for Pharmacogenetics  
**Pui-Yan Kwok,** University of California, San Francisco, San Francisco, CA, USA

Pharmacogenetics: Views from the Pharmaceutical Industry*  
**Eric H. Lai,** GlaxoSmithKline, Research Triangle Park, NC, USA

3:30 PM - 5:30 PM  
**Concurrent Session 2: Ultra-High Throughput Sequencing Technologies: Towards Patient Genome Sequencing**  
Meeting Room 303-305, Level 3

**Co-Chairpersons:** Yijun Ruan and Chia Lin Wei, Genome Institute of Singapore, Singapore

The Future is Now: Single Molecule DNA Sequencing  
**Stephen Quake,** Stanford University, Stanford, CA, USA

Applications of Ultra-High Throughput Sequencing  
**Michael Egholm,** 454 Life Sciences, Branford, CT, USA

Enabling Key Applications with the SOLiD™ System*  
**Robert Nutter,** Applied Biosystems, Foster City, CA, USA

Enabling Genome Biology with Solexa Next Generation Sequencing Technology  
**Gary P. Schroth,** Illumina, Inc, Hayward, CA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.*
3:30 PM-5:30 PM  Concurrent Session 3:  
Hereditary Cancers  
Meeting Room 325-326, Level 3  

Co-Chairpersons:  Ivy Ng, KK Women’s and Children’s Hospital, Singapore; Kon Oi Lian, National Cancer Centre, Singapore  

Identification of Host Genetic Factors Important for Breast Cancer Susceptibility and Prognosis  
Edison T. Liu and Jian-Jun Liu, Genome Institute of Singapore, Singapore  

The Discovery and Validation of Biomarkers that Predict Response to Novel Cancer Therapeutics  
Richard Wooster, GlaxoSmithKline, Narbeth, PA, USA  

Using Genetics to Individualize Therapy in Breast Cancer  
Olufunmilayo I. Olopade, University of Chicago Medical Center, Chicago, IL, USA  

Recent Advances in Familial Colorectal Cancer Genetics and Diagnostics*  
Peh Yean Cheah, Singapore General Hospital, Singapore  

11:30 AM-1:00 PM  Poster Session C  
Ballroom 1, Level 2  

1:00 PM-3:00 PM  Plenary Session 6:  
Clinical Intervention and Populations Outcomes:  
Global Strategies  
Ballroom 2, Level 2  

Co-Chairpersons:  Chia Kee Seng, National University of Singapore, Singapore; Chien Earn Lee, Ministry of Health, Singapore  

Normalization of Tumor Vasculature and Microenvironment by Antiangiogenic Therapies: From the Bench to Bedside and Back*  
Rakesh K. Jain, Massachusetts General Hospital, Boston, MA, USA  

Role of Anti-EGFR Therapy in Asian Cancer Patients*  
Yung-Jue Bang, Seoul National University College of Medicine, Seoul, Republic of Korea  

Early Detection Is the Key to Improving Survival in Gastric Cancer  
Khay-Guan Yeoh, National University of Singapore, Singapore  

HPV Vaccine Development  
Douglas R. Lowy, National Cancer Institute, NIH, Bethesda, MD, USA  

Wednesday, November 7, 2007  

8:00 AM-7:30 PM  Exhibits  
Ballroom Foyer, Level 2  

9:00 AM-11:30 AM  Plenary Session 5:  
Cancer Stem Cells  
Ballroom 2, Level 2  

Co-Chairpersons:  Alan Coleman, Institute of Medical Biology, Singapore; Ng Huck Hui, National University of Singapore, Singapore  

Cellular Genomics  
Spyro Mousses, TGen, Scottsdale, AZ, USA  

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.
**3:00 PM-3:30 PM**  
**Refreshment Break**  
Ballroom Foyer, Level 2

**3:30 PM-5:30 PM**  
**Concurrent Session 4: Cancer Prevention**  
Meeting Room 301-302, Level 3

*Chairperson: Mabel Yap, Ministry of Health, Singapore*

Preventing Colorectal Neoplasia Methods: Means and Myths*
*John D. Potter*, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Diverse Mechanisms of Carcinogenesis by RUNX Gene Family
*Yoshiaki Ito*, Institute of Molecular and Cell Biology, Singapore

Cyclin D1 as a Target for Cancer Chemoprevention*
*Ethan Dmitrovsky*, Dartmouth Medical School, Hanover, NH, USA

Global Cancer Control: One Size Fits Very Little
*Peter Boyle*, International Agency for Research on Cancer, Lyon, France

**3:30 PM-5:30 PM**  
**Concurrent Session 5: Advances in Cancer Therapeutics**  
Meeting Room 303-305, Level 3

*Co-Chairpersons: Toh Eng Huat*, National University of Singapore, Singapore; *Mickey Koh*, Singapore General Hospital, Singapore

Adoptive Immunotherapy with Zinc Finger Nuclease Engineered T Cells
*Carl H. June*, University of Pennsylvania, Philadelphia, PA, USA

How to Explore PHY906, a Chinese Medicine Formula, as Adjuvant Therapy for Cancer
*Yung-chi Cheng*, Yale University School of Medicine, New Haven, CT, USA

**3:30 PM-5:30 PM**  
**Concurrent Session 6: Systems Medicine**  
Meeting Room 325-326, Level 3

*Co-Chairperson: Edison T. Liu*, Genome Institute of Singapore, Singapore; *Patrick J. Casey*, Duke University Medical Center, Durham, NC, USA

Title to be announced
*Chi Van Dang*, Johns Hopkins University School of Medicine, Baltimore, MD, USA

A PK/PD and Systems Biology Approach for Anti-angiogenic Drug Discovery*
*Jonathan M. Yingling*, Eli Lilly and Company, Indianapolis, IN, USA

A Robustness-based Approach to Systems-oriented Drug Design*
*Hiroaki Kitano*, The Systems Biology Institute, Tokyo, Japan

Genomic and Epigenomic Profiling in Cancer*
*Hiroyuki Aburatani*, University of Tokyo, Tokyo, Japan

**5:30 PM-7:30 PM**  
**Poster Session C (continued)**  
Ballroom 1, Level 2

**8:00 PM-10:00 PM**  
**Conference Banquet**  
Raffles Ballroom, Swissotel The Stamford

All conference registrants are invited to attend.

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.*
Thursday, November 8, 2007

8:00 AM-9:00 AM Special Session
Late-Breaking Abstract in Translational and Clinical Cancer Medicine
Ballroom 2, Level 2

Co-Chairpersons: Edison T. Liu, Genome Institute of Singapore, Singapore; William N. Hait, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ, USA

LB-01 A phase II clinical trial of melanoma tumor-lysate-pulsed autologous dendritic cell vaccination in advanced colorectal cancer patients expressing the MAGE family antigen/s.
Toh Han Chong, National Cancer Centre, Singapore

LB-02 Early prediction of antiepidermal growth factor receptor therapy with 18[F]FDG-PET: A preclinical and clinical correlation
Wen W. Ma, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

LB-03 A58 Genetic polymorphisms and minimal residual disease in childhood acute lymphoblastic leukemia: Malaysia-Singapore (Ma-Spore) ALL 2003 study
Shirley Kow Yin Kham, National University of Singapore, Singapore

Additional speaker to be announced

9:15 AM-11:45 AM Plenary Session 7: Target to Lead: New Strategies in Drug Development
Ballroom 2, Level 2

Co-Chairpersons: David M. Virshup, Duke-NUS Graduate Medical School, Singapore; Jeanette Wood, S*BIO, Singapore

Drug Discovery in the p53 Pathway
David P. Lane, Institute of Molecular and Cell Biology, Singapore

From Cancer Genomics to Cancer Treatment*
Yusuke Nakamura, University of Tokyo, Tokyo, Japan

Targeting Epigenetic Process for Therapeutic Control of Wnt/β-catenin Signaling in Colorectal Cancer*
Qiang Yu, Genome Institute of Singapore, Singapore

Functional and Prognostic Insights into the Altered Cancer Genome*
Lance D. Miller, Genome Institute of Singapore, Singapore

11:45 AM-12:00 PM Closing Session: Concluding Remarks
Ballroom 2, Level 2

Edison T. Liu, Genome Institute of Singapore, Singapore

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings.